Short Bowel Syndrome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Distribution Channel, By Region and Competition, 2020-2030F

Description

The global Short Bowel Syndrome (SBS) market was valued at USD 854.02 million in 2024 and is projected to reach USD 1,265.38 million by 2030, reflecting a compound annual growth rate (CAGR) of 6.73% over the forecast period. SBS is a rare and debilitating condition that impacts the digestive system, particularly the small intestine. Individuals with SBS experience a reduced ability to absorb nutrients and fluids, which can result in malnutrition, dehydration, and various other health complications. In recent years, the global SBS market has experienced significant advancements, bringing new hope to patients and healthcare providers alike.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 854.02 Million
Market Size 2030	USD 1265.38 Million
CAGR 2025-2030	6.73%
Fastest Growing Segment	Glutamine
Largest Market	North America

SBS typically arises from the surgical removal or damage of a substantial portion of the small intestine, often caused by factors such as congenital defects, trauma, or diseases like Crohn's disease. According to a recent study titled "Crohn's Disease Phenotypes and Associations With Comorbidities, Surgery Risk, Medications, and Nonmedication Approaches: The MAGIC in IMAGINE Study", a study in Japan on 673 newly diagnosed adults with Crohn's disease (CD) found that 63% exhibited an inflammatory phenotype, 60% had ileocolonic disease, and 49% had perianal lesions, with the prevalence of perianal disease (such as abscesses or fistulas) being notably high. Studies across Asia have reported even higher rates of inflammatory disease, ranging from 66% to 81%.

Key Market Drivers

The increasing incidence of Short Bowel Syndrome is driving market growth. As the number of SBS cases rises, the demand for treatments and therapies has surged, contributing to the market's expansion. Pharmaceutical companies are heavily investing in research and development to create medications that enhance nutrient absorption for SBS patients and help them manage their condition. These innovations are a significant factor in the market's growth. Parenteral nutrition, which delivers essential nutrients intravenously, has become a critical treatment for SBS patients, leading to a rise in demand for these solutions and associated equipment. Additionally, enteral nutrition, involving specialized formulas designed for SBS patients, plays a crucial role in managing the condition. Advances in minimally invasive surgical techniques and small bowel transplantation have also improved patient outcomes, further driving market expansion. Increased awareness of SBS and the advocacy efforts of patient groups have led to additional research funding and resources, fostering further market growth. Although SBS is rare, with an estimated prevalence of 1-2 cases per 100,000 individuals annually, its growing recognition is accelerating the development of treatment options.

Key Market Challenges

A major challenge for the SBS market is the limited patient pool. As SBS is classified as a rare disease, the number of diagnosed cases globally is relatively small, limiting the overall market size and the number of patients requiring specialized treatments. This restricted patient base can deter pharmaceutical companies from investing heavily in the development of new therapies, as the potential return on investment is lower. Consequently, promising treatments may not receive the attention they deserve, hindering progress in the field. Additionally, the fragmented nature of the patient pool complicates large-scale clinical trials and the collection of sufficient data to prove the efficacy of new therapies, creating a cycle of underinvestment and delayed progress.

Key Market Trends

Technological advancements have significantly influenced the growth of the global SBS market. Recent medical innovations are improving the management and treatment of SBS, offering hope for affected individuals. Pharmaceutical companies are actively developing new drugs and therapies to address the causes and symptoms of SBS. A notable advancement is Zealand Pharma A/S's phase 3 study of Glepaglutide, a long-acting GLP-2 analog that could potentially outperform existing treatments, such as Teduglutide, due to its benefits, including weekly administration and extended action. Furthermore, the development of specialized nutritional supplements tailored for SBS patients has greatly improved their quality of life.

Key Market Players

Wellspect Healthcare (Dentsply Sirona Company)
Emmaus Life Sciences, Inc.
Merck & Co., Inc.
Novartis AG
OPKO Health, Inc.
OxThera AB
Pfizer Inc.
Swedish Orphan Biovitrum AB
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.

Report Scope

This report provides a detailed analysis of the global Short Bowel Syndrome market, segmented into the following categories, in addition to examining industry trends:

By Drug Class:

GLP-2
Glutamine
Growth Hormone

By Distribution Channel:

Hospital Pharmacies
Online Sales
Retail Pharmacies

By Region:

North America:
United States
Canada
Mexico
Europe:
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific:
China
India
Japan
Australia
South Korea
South America:
Brazil
Argentina
Colombia
Middle East & Africa:
South Africa
Saudi Arabia
UAE

Competitive Landscape

This report includes detailed profiles of the leading companies operating in the SBS market.

Available Customizations: TechSci Research offers tailored customizations of the Global Short Bowel Syndrome market report to meet specific business requirements. The following customization options are available:

Company Information: In-depth analysis and profiling of additional market players (up to five).

Product Code: 19143

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Short Bowel Syndrome Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Drug Class (GLP-2, Glutamine, and Growth Hormone)
- 5.2.2. By Distribution Channel (Hospital Pharmacies, Online Sales, and Retail Pharmacies)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America Short Bowel Syndrome Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Drug Class
- 6.2.2. By Distribution Channel
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Short Bowel Syndrome Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Drug Class
    - 6.3.1.2.2. By Distribution Channel
- 6.3.2. Canada Short Bowel Syndrome Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Drug Class
    - 6.3.2.2.2. By Distribution Channel
- 6.3.3. Mexico Short Bowel Syndrome Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Drug Class
    - 6.3.3.2.2. By Distribution Channel

7. Europe Short Bowel Syndrome Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Drug Class
- 7.2.2. By Distribution Channel
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Short Bowel Syndrome Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Drug Class
    - 7.3.1.2.2. By Distribution Channel
- 7.3.2. United Kingdom Short Bowel Syndrome Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Drug Class
    - 7.3.2.2.2. By Distribution Channel
- 7.3.3. Italy Short Bowel Syndrome Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Drug Class
    - 7.3.3.2.2. By Distribution Channel
- 7.3.4. France Short Bowel Syndrome Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Drug Class
    - 7.3.4.2.2. By Distribution Channel
- 7.3.5. Spain Short Bowel Syndrome Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Drug Class
    - 7.3.5.2.2. By Distribution Channel

8. Asia-Pacific Short Bowel Syndrome Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Drug Class
- 8.2.2. By Distribution Channel
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Short Bowel Syndrome Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Drug Class
    - 8.3.1.2.2. By Distribution Channel
- 8.3.2. India Short Bowel Syndrome Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Drug Class
    - 8.3.2.2.2. By Distribution Channel
- 8.3.3. Japan Short Bowel Syndrome Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Drug Class
    - 8.3.3.2.2. By Distribution Channel
- 8.3.4. South Korea Short Bowel Syndrome Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Drug Class
    - 8.3.4.2.2. By Distribution Channel
- 8.3.5. Australia Short Bowel Syndrome Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Drug Class
    - 8.3.5.2.2. By Distribution Channel

9. South America Short Bowel Syndrome Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Drug Class
- 9.2.2. By Distribution Channel
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Short Bowel Syndrome Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Drug Class
    - 9.3.1.2.2. By Distribution Channel
- 9.3.2. Argentina Short Bowel Syndrome Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Drug Class
    - 9.3.2.2.2. By Distribution Channel
- 9.3.3. Colombia Short Bowel Syndrome Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Drug Class
    - 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Short Bowel Syndrome Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Drug Class
- 10.2.2. By Distribution Channel
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Short Bowel Syndrome Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Drug Class
    - 10.3.1.2.2. By Distribution Channel
- 10.3.2. Saudi Arabia Short Bowel Syndrome Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Drug Class
    - 10.3.2.2.2. By Distribution Channel
- 10.3.3. UAE Short Bowel Syndrome Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Drug Class
    - 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Porter's Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products

14. Competitive Landscape

14.1. Wellspect Healthcare (Dentsply Sirona Company)
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
14.2. Emmaus Life Sciences, Inc.
14.3. Merck & Co., Inc.
14.4. Novartis AG
14.5. OPKO Health, Inc.
14.6. OxThera AB
14.7. Pfizer Inc.
14.8. Swedish Orphan Biovitrum AB
14.9. Takeda Pharmaceutical Company Limited
14.10. Teva Pharmaceutical Industries Ltd.